Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Target Price at $6.22

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been assigned an average rating of “Buy” from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $6.38.

A number of equities analysts have recently commented on TSHA shares. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a report on Thursday, June 20th. BMO Capital Markets initiated coverage on Taysha Gene Therapies in a research note on Thursday, June 27th. They issued an “outperform” rating and a $5.00 target price for the company. Needham & Company LLC reduced their target price on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a report on Monday, August 12th. Piper Sandler lowered their price target on shares of Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating on the stock in a report on Monday, July 1st. Finally, Canaccord Genuity Group reduced their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th.

Insider Transactions at Taysha Gene Therapies

In related news, major shareholder Paul B. Manning purchased 1,333,333 shares of the firm’s stock in a transaction dated Thursday, June 27th. The shares were purchased at an average price of $2.25 per share, with a total value of $2,999,999.25. Following the acquisition, the insider now directly owns 1,333,333 shares of the company’s stock, valued at $2,999,999.25. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. bought a new stake in shares of Taysha Gene Therapies in the 4th quarter valued at about $28,000. Dynamic Technology Lab Private Ltd purchased a new position in Taysha Gene Therapies in the 4th quarter worth approximately $31,000. Avoro Capital Advisors LLC lifted its position in Taysha Gene Therapies by 11.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 4,355,555 shares of the company’s stock valued at $7,709,000 after purchasing an additional 430,555 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of Taysha Gene Therapies during the fourth quarter valued at approximately $370,000. Finally, Chicago Partners Investment Group LLC grew its holdings in shares of Taysha Gene Therapies by 21.4% in the fourth quarter. Chicago Partners Investment Group LLC now owns 134,851 shares of the company’s stock worth $239,000 after purchasing an additional 23,740 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Down 1.8 %

Shares of NASDAQ TSHA opened at $2.15 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22. The stock has a market capitalization of $440.62 million, a PE ratio of -4.39 and a beta of 0.41. Taysha Gene Therapies has a one year low of $1.27 and a one year high of $4.32. The business’s fifty day moving average price is $2.20 and its 200-day moving average price is $2.59.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $3.62 million. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. During the same period in the prior year, the company posted ($0.38) EPS. On average, equities research analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.